U.S. Mesenchymal Stem Cells Market Size & Outlook
U.S. mesenchymal stem cells market, 2018-2030 (US$M)
Related Markets
U.S. mesenchymal stem cells market highlights
- The U.S. mesenchymal stem cells market generated a revenue of USD 1,329.6 million in 2023 and is expected to reach USD 2,949.6 million by 2030.
- The U.S. market is expected to grow at a CAGR of 12.1% from 2024 to 2030.
- In terms of segment, product was the largest revenue generating product & services in 2023.
- Services is the most lucrative product & services segment registering the fastest growth during the forecast period.
Mesenchymal stem cells market data book summary
| Market revenue in 2023 | USD 1,329.6 million |
| Market revenue in 2030 | USD 2,949.6 million |
| Growth rate | 12.1% (CAGR from 2023 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Services |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Services |
| Key market players worldwide | Thermo Fisher Scientific Inc, STEMCELL Technologies, Merck KGaA, Lonza Group Ltd, PromoCell GmbH, Cyagen Biosciences, Stemedica Cell Technologies, Axol Bioscience, Celprogen, Cellcolabs, Visual Photonics Epitaxy |
Other key industry trends
- In terms of revenue, U.S. accounted for 42.6% of the global mesenchymal stem cells market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. mesenchymal stem cells market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 230.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Mesenchymal Stem Cells Market Scope
Mesenchymal Stem Cells Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. mesenchymal stem cells market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mesenchymal stem cells market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 79.49% in 2023. Horizon Databook has segmented the U.S. mesenchymal stem cells market based on product, services covering the revenue growth of each sub-segment from 2018 to 2030.
Robust support from regulatory authorities is set to propel the mesenchymal stem cell market growth in the U.S. For instance, in April 2020, a team of researchers in the U.S. received FDA approval to initiate the clinical trial for evaluating umbilical cord-derived Mesenchymal Stem Cells (MSCs) to prevent lung inflammation in severe COVID-19 cases.
Such approvals are expected to aid the adoption of MSCs over the forecast period. Furthermore, increased funding from government and private organizations is expected to drive the demand in the U.S. MSC market.
For instance, in January 2022, Cellino Biotech announced that it raised around USD 80 million through a Series A financing round from 8VC, Felicis Ventures, and other investors. The company plans to use these funds to expand access to stem cell-derived therapies to develop the first independent human cell foundry by 2025.
Reasons to subscribe to U.S. mesenchymal stem cells market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. mesenchymal stem cells market databook
-
Our clientele includes a mix of mesenchymal stem cells market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. mesenchymal stem cells market , including forecasts for subscribers. This country databook contains high-level insights into U.S. mesenchymal stem cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. mesenchymal stem cells market size, by product & services, 2018-2030 (US$M)
U.S. Mesenchymal Stem Cells Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
